■已知尿路上皮癌(SUC)的亚型具有组织学亚型或分化分化的形态多样性。然而,阿维鲁单抗对SUC的疗效尚不清楚.因此,在晚期SUC患者中,阿维鲁单抗单药治疗的疗效和生存结果作为一线治疗维持治疗进行了评估.
■对九州研究人群中来自下尿路肿瘤组的连续患者进行了回顾性分析,这些患者在一线铂类化疗后接受了阿维鲁单抗维持治疗而没有进展。对单纯尿路上皮癌(PUC)和SUC患者进行客观缓解率(ORR)对比分析,疾病控制率,无进展生存期(PFS),总生存率(OS)。
■在49名记录的患者中,38和11有PUC和SUC,分别。最常见的亚型元素是腺体分化(n=5),其次是鳞状分化(n=3),微乳头状(n=1),和浆细胞样亚型(n=1)。SUC和PUC组的ORR相当(0%vs.2.6%,P>0.99)和疾病控制率(54.5%vs.44.7%,P=0.73)。这些患者组的PFS也没有显着差异(中位数3.9与3.1个月,P=0.33)或OS(中位数16.7vs.22.1个月,P=0.47)。
■在晚期下尿路和上尿路癌患者中,SUC和PUC对avelumab的反应相当,表明avelumab维持治疗对SUC也有效。
UNASSIGNED: The subtype of urothelial carcinoma (SUC) has been known to possess morphological diversity for histologic subtype or divergent differentiation. However, the efficacy of
avelumab against SUC remains unclear. Therefore, the effect of the treatment as well as the survival results of
avelumab monotherapy were evaluated as a first-line therapeutic maintenance in patients with advanced SUC.
UNASSIGNED: A retrospective analysis was conducted on consecutive patients from the Uro-Oncology Group in Kyushu study population with advanced lower and upper urinary tract cancer who underwent
avelumab maintenance therapy without progression after first-line platinum-based chemotherapy. Patients with pure urothelial carcinoma (PUC) and SUC were comparatively analyzed based on objective response rate (ORR), disease control rate, progression-free survival (PFS), and overall survival (OS).
UNASSIGNED: Out of 49 recorded patients, 38 and 11 had PUC and SUC, respectively. The most common subtype element was glandular differentiation (n=5), followed by squamous differentiation (n=3), micropapillary (n=1), and plasmacytoid subtypes (n=1). The SUC and PUC groups had comparable ORR (0% vs. 2.6%, P>0.99) and disease control rates (54.5% vs. 44.7%, P=0.73). These patient groups also showed no significant difference in PFS (median 3.9 vs. 3.1 months, P=0.33) or OS (median 16.7 vs. 22.1 months, P=0.47).
UNASSIGNED: The response of SUC and PUC to
avelumab was comparable in patients with advanced lower and upper urinary tract cancer, indicating that
avelumab maintenance therapy is also effective for SUC.